Yanping Bao1, Sarah Larney2, Amy Peacock2, Samantha Colledge2, Jason Grebely3, Matthew Hickman4, Louisa Degenhardt2, Janni Leung5. 1. National Institute on Drug Dependence, Peking University, Beijing, China; National Drug and Alcohol Research Centre, UNSW Sydney, Sydney, Australia. 2. National Drug and Alcohol Research Centre, UNSW Sydney, Sydney, Australia. 3. The Kirby Institute, UNSW Sydney, Sydney, NSW, Australia. 4. Population Health Science, Bristol Medical School, University of Bristol, Bristol, UK. 5. National Drug and Alcohol Research Centre, UNSW Sydney, Sydney, Australia; Centre for Youth Substance Abuse Research, The University of Queensland, Brisbane, Australia. Electronic address: j.leung1@uq.edu.au.
Abstract
BACKGROUND: Globally, China is the largest country by population and contributes substantially to the burden of people who inject drugs (PWID). The aims of this study were to estimate the prevalence of HIV, hepatitis C virus (HCV) and hepatitis B virus (HBV) among PWID at the national and subnational level in China and examine characteristics of PWID. METHODS: We undertook a systematic review of studies published from 2008 to 2017 on HIV, HCV, and HBV seroprevalence among PWID, and characteristics of PWID in Mainland China, Hong Kong, Macao and Taiwan. Meta-analyses were conducted to generate pooled prevalence estimates by province, region, and nationally. RESULTS: Eighty-five papers were included. The pooled HIV, HCV antibody and HBV prevalence among PWID in China was 10.5% (95% confidence interval [95%CI]: 8.6%-12.5%), 71.6% (65.7%-77.6%) and 19.6% (13.7%-25.5%), respectively. In Mainland China, HIV prevalence was highest in the Southwest (14.4%, 10.5%-18.4%) and lowest in the North (1.3%, 0.4%-3.4%). Xinjiang Province had the highest HIV prevalence (42.6%, 35.5%-49.8%). HCV antibody prevalence was highest in the Southwest (77.7%, 69.9%-85.4%), followed by South (76.2%, 65.9%-86.4%). Sichuan had the highest HCV antibody prevalence (91.7%, 86.6%-95.3%), followed by Guangxi (86.1%, 81.8%-90.4%). HBsAg prevalence among PWID was highest in South (25.3%, 14.6%-36.0%), followed by Central (20.8%, 17.4%-24.1%). HBsAg prevalence ranged from 2.4% (0.6-5.9%) in Guizhou to 40.0% (33.7%-46.6%) in Shannxi Province. In China, women and young people accounted for 21.3% and 23.1% of PWID, respectively. It was estimated that 96.1% of PWID injected opioids mainly, and recent injecting risk and sexual risk was reported by 28.5% and 36.7%. CONCLUSION: There is a large burden of HIV, HCV and HBV prevalence among PWID in China, with considerable geographic variation. The disease burden of viral hepatitis is particularly high, implying that effective management should be integrated into harm reduction interventions among PWID in China.
BACKGROUND: Globally, China is the largest country by population and contributes substantially to the burden of people who inject drugs (PWID). The aims of this study were to estimate the prevalence of HIV, hepatitis C virus (HCV) and hepatitis B virus (HBV) among PWID at the national and subnational level in China and examine characteristics of PWID. METHODS: We undertook a systematic review of studies published from 2008 to 2017 on HIV, HCV, and HBV seroprevalence among PWID, and characteristics of PWID in Mainland China, Hong Kong, Macao and Taiwan. Meta-analyses were conducted to generate pooled prevalence estimates by province, region, and nationally. RESULTS: Eighty-five papers were included. The pooled HIV, HCV antibody and HBV prevalence among PWID in China was 10.5% (95% confidence interval [95%CI]: 8.6%-12.5%), 71.6% (65.7%-77.6%) and 19.6% (13.7%-25.5%), respectively. In Mainland China, HIV prevalence was highest in the Southwest (14.4%, 10.5%-18.4%) and lowest in the North (1.3%, 0.4%-3.4%). Xinjiang Province had the highest HIV prevalence (42.6%, 35.5%-49.8%). HCV antibody prevalence was highest in the Southwest (77.7%, 69.9%-85.4%), followed by South (76.2%, 65.9%-86.4%). Sichuan had the highest HCV antibody prevalence (91.7%, 86.6%-95.3%), followed by Guangxi (86.1%, 81.8%-90.4%). HBsAg prevalence among PWID was highest in South (25.3%, 14.6%-36.0%), followed by Central (20.8%, 17.4%-24.1%). HBsAg prevalence ranged from 2.4% (0.6-5.9%) in Guizhou to 40.0% (33.7%-46.6%) in Shannxi Province. In China, women and young people accounted for 21.3% and 23.1% of PWID, respectively. It was estimated that 96.1% of PWID injected opioids mainly, and recent injecting risk and sexual risk was reported by 28.5% and 36.7%. CONCLUSION: There is a large burden of HIV, HCV and HBV prevalence among PWID in China, with considerable geographic variation. The disease burden of viral hepatitis is particularly high, implying that effective management should be integrated into harm reduction interventions among PWID in China.
Authors: Gretchen A Stevens; Leontine Alkema; Robert E Black; J Ties Boerma; Gary S Collins; Majid Ezzati; John T Grove; Daniel R Hogan; Margaret C Hogan; Richard Horton; Joy E Lawn; Ana Marušić; Colin D Mathers; Christopher J L Murray; Igor Rudan; Joshua A Salomon; Paul J Simpson; Theo Vos; Vivian Welch Journal: Lancet Date: 2016-06-28 Impact factor: 79.321
Authors: Sarah Larney; Amy Peacock; Janni Leung; Samantha Colledge; Matthew Hickman; Peter Vickerman; Jason Grebely; Kostyantyn V Dumchev; Paul Griffiths; Lindsey Hines; Evan B Cunningham; Richard P Mattick; Michael Lynskey; John Marsden; John Strang; Louisa Degenhardt Journal: Lancet Glob Health Date: 2017-10-23 Impact factor: 26.763
Authors: Xiaochen Chen; Xing Liu; Song Duan; Renhai Tang; Sujuan Zhou; Runhua Ye; Yuecheng Yang; Jibao Wang; Shitang Yao; Na He Journal: Int J Environ Res Public Health Date: 2020-12-17 Impact factor: 3.390
Authors: Jasmine Yee; Joanne M Carson; Behzad Hajarizadeh; Joshua Hanson; James O'Beirne; David Iser; Phillip Read; Anne Balcomb; Joseph S Doyle; Jane Davies; Marianne Martinello; Philiipa Marks; Gregory J Dore; Gail V Matthews Journal: Hepatol Commun Date: 2021-11-02